Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...

-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal ...

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.71%. A quarter ago, it was expected that this company would post a loss of $0.26 per share when it actually produced a loss of $0.35, delivering a surprise of -34.62%. Over the last four quarters, the company h ...

– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasda ...

Core Viewpoint - Lyra Therapeutics is implementing significant workforce reductions and cost-cutting measures to extend its cash runway and focus on ongoing clinical trials for its product LYR-210, a treatment for chronic rhinosinusitis (CRS) [1][3][4]. Group 1: Workforce and Cost-Cutting Measures - The company is laying off approximately 75% of its workforce, affecting 87 employees, and has halted manufacturing and commercialization efforts [1][3]. - Lyra Therapeutics is seeking to sublease its facilities to significantly reduce operating costs and has paused efforts for another product candidate, LYR-220 [3][4]. - These measures are expected to extend the company's cash runway into 2026, with approximately $87.1 million in cash, cash equivalents, and short-term investments as of March 31, 2024 [3]. Group 2: Clinical Trials Focus - Lyra is concentrating on two ongoing ENLIGHTEN Phase 3 trials for LYR-210, which is a bioabsorbable sinonasal implant for CRS treatment [2][5]. - The ENLIGHTEN 1 trial did not meet its 24-week primary endpoint, and the company is analyzing this data to inform the completion of the 52-week extension phase, with results expected in Q4 2024 [2][5]. - The ENLIGHTEN program includes two randomized, blinded, sham-controlled trials designed to evaluate the efficacy and safety of LYR-210 in 180 CRS patients who have failed medical management [5][6]. Group 3: Product Information - LYR-210 is designed to deliver six months of continuous anti-inflammatory medication (7500µg mometasone furoate) to treat CRS, which affects up to four million patients annually in the U.S. [7][9]. - The product is intended for patients who have not undergone ethmoid sinus surgery, while LYR-220 is designed for those with enlarged nasal cavities due to previous surgeries [9].

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures. In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR- 210, a bioabsorbable sinonasal implant for the treatment of chronic rhinosinusitis (CRS). Lyra continues to analyz ...

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -34.62%. A quarter ago, it was expected that this company would post a loss of $0.33 per share when it actually produced a loss of $0.22, delivering a surprise of 33.33%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. | Large accelerated filer | ☐ | Accelerated filer | ☐ | | - ...

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update WATERTOWN, Mass., April 30, 2024 -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. "With results imminent for our ENLIGHTEN 1 pivotal Ph ...

WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The ...